Skip to main content
main-content
Top

24-09-2020 | Diabetes | News | Article

EASD 2020

Further VERTIS-CV analysis supports ertugliflozin renal benefits

Author:
Eleanor McDermid

medwireNews: The VERTIS-CV investigators have presented further kidney outcomes data, supporting the renoprotective effects of the sodium-glucose cotransporter (SGLT)2 inhibitor medication class.

The renal composite endpoint that the team originally reported with the primary outcome data was renal death, dialysis/transplant, or doubling of serum creatinine. This occurred in 3.2% of the ertugliflozin group (5 or 15 mg, n=5499) versus 3.9% of the placebo group (n=2747), for a nonsignificant 19% difference favoring the SGLT2 inhibitor.

Speaking at the virtual 56th EASD Annual Meeting, David Cherney (University of Toronto, Ontario, Canada) reported that this trend continued when they looked at other kidney endpoints, with all showing at least numerically improved rates in the ertugliflozin group.

And there was a significant reduction in the composite endpoint of a sustained 40% reduction in estimated glomerular filtration rate (eGFR), dialysis/transplant, or renal death, which occurred in 2.05% versus 3.09% of the ertugliflozin versus placebo groups, for a 36% reduction. This was driven mainly by a smaller proportion of people in the ertugliflozin versus placebo groups experiencing an eGFR decline; the other two endpoints were very rare.

The improvements in this combined endpoint with ertugliflozin were seen across categories of baseline kidney function and regardless of the definition used.

VERTIS-CV participants taking ertugliflozin also had a reduced risk for progressing to a higher category of albuminuria and an increased likelihood for regressing to a lower category. Notably, these benefits appeared to be greater for people who had microalbuminuria rather than normoalbuminuria at baseline, and, in the case of progression, for people in the KDIGO chronic kidney disease moderate- and high-risk as opposed to low-risk categories.

As expected with an SGLT2 inhibitor, people taking ertugliflozin experienced an acute decline in eGFR, but this returned to a level similar to that in the placebo group after a few months. After month 24, the eGFR trajectories diverged so that it remained relatively stable in people taking ertugliflozin but declined in those taking placebo. By month 60 there was a significant difference of 2.55 mL/min per 1.73 m2 between the two groups, favoring ertugliflozin. This difference was most marked in people who had macroalbuminuria at baseline.

“The results of VERTIS CV provide further evidence supporting the beneficial effects of this drug class on [cardiovascular] and renal outcomes,” Cherney concluded.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group

EASD virtual meeting; 21–25 September 2020


See the research in context now

with trial summaries, expert opinion and congress coverage